Mark Frydenberg

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9309990/mark-frydenberg-publications-by-year.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83
papers

3,511
30
h-index

92
ext. papers

5,002
ext. citations

7.3
avg, IF

4.94
L-index

#	Paper	IF	Citations
83	How Does Age Affect Urinary Continence following Robot-Assisted Radical Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires <i>Journal of Urology</i> , 2022 , 101097JU000000000002391	2.5	O
82	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021 <i>European Urology</i> , 2022 ,	10.2	2
81	Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?. <i>Investigative and Clinical Urology</i> , 2021 , 62, 650-657	1.9	1
80	Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta-analysis. <i>BJU International</i> , 2021 ,	5.6	2
79	Oxytocin receptor antagonists as a novel pharmacological agent for reducing smooth muscle tone in the human prostate. <i>Scientific Reports</i> , 2021 , 11, 6352	4.9	
78	Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival. <i>European Journal of Cancer</i> , 2021 , 148, 440-450	7.5	3
77	An integrated multicomponent care model for men affected by prostate cancer: A feasibility study of TrueNTH Australia. <i>Psycho-Oncology</i> , 2021 , 30, 1544-1554	3.9	2
76	Patterns of care for prostate cancer treatment and improving outcomes - are national registries the answer?. <i>BJU International</i> , 2021 , 128 Suppl 1, 6-8	5.6	O
75	Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial. <i>World Journal of Urology</i> , 2021 , 39, 4117-4125	4	
74	High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids. <i>SLAS Discovery</i> , 2021 , 26, 1107-1124	3.4	1
73	Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. <i>European Urology</i> , 2021 , 79, 413-418	10.2	15
72	Predictors of erectile dysfunction after transperineal template prostate biopsy. <i>Investigative and Clinical Urology</i> , 2021 , 62, 159-165	1.9	O
71	Combined Utility of Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology. <i>European Urology Oncology</i> , 2021 ,	6.7	1
70	The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. <i>Nature Communications</i> , 2021 , 12, 5049	17.4	6
69	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. <i>European Urology</i> , 2021 , 80, 275-279	10.2	3
68	Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography Maximum Standardized Uptake Value as a Predictor of Gleason Pattern 4 and Pathological Upgrading in Intermediate-Risk Prostate Cancer. <i>Journal of Urology</i> , 2021 , 101097JU000000000002254	2.5	О
67	Knowing what's growing: Why ductal and intraductal prostate cancer matter. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	13

(2019-2020)

66	Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer. <i>Clinical Epigenetics</i> , 2020 , 12, 48	7.7	11
65	Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. <i>Lancet, The</i> , 2020 , 395, 1208-1216	40	472
64	Prostate cancer survivorship essentials framework: guidelines for practitioners. <i>BJU International</i> , 2020 ,	5.6	12
63	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020 , 77, 508-547	10.2	155
62	Contemporary consumer perspectives on prostate cancer survivorship: Fifty voices. <i>Psycho-Oncology</i> , 2020 , 29, 557-563	3.9	7
61	The role of open radical nephrectomy in contemporary management of renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2020 , 9, 3123-3139	2.3	O
60	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. <i>European Urology</i> , 2020 , 77, 223-250	10.2	60
59	Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologists. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 929.e1-929.e10	2.8	3
58	Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. <i>Lancet Oncology, The</i> , 2020 , 21, 1331-1340	21.7	80
57	Can Exercise Adaptations Be Maintained in Men with Prostate Cancer Following Supervised Programmes? Implications to the COVID-19 Landscape of Urology and Clinical Exercise. <i>European Urology Open Science</i> , 2020 , 21, 47-50	0.9	2
56	Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial. <i>International Journal of Cancer</i> , 2020 , 146, 161-168	7.5	29
55	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundations Global Action Plan Prostate Cancer Active Surveillance Initiative. <i>European Urology Oncology</i> , 2020 , 3, 80-91	6.7	11
54	A feasibility and acceptability study of an adaptation of the Mindful Self-Compassion program for adult cancer patients. <i>Palliative and Supportive Care</i> , 2020 , 18, 130-140	2.5	10
53	Detection and localisation of primary prostate cancer using gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. <i>BJU International</i> ,	5.6	31
52	Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer. Prostate, 2019 , 79, 1326-1337	4.2	10
51	High ductal proportion predicts biochemical recurrence in prostatic ductal adenocarcinoma. <i>BJU International</i> , 2019 , 124, 907-909	5.6	4
50	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 121-131	59.2	479
49	Work after prostate cancer: a systematic review. <i>Journal of Cancer Survivorship</i> , 2019 , 13, 282-291	5.1	8

48	Re: Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2019 , 76, 405	10.2	
47	Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	116
46	Quality of life considerations in the treatment of metastatic hormone-sensitive prostate cancer. <i>Lancet Oncology, The</i> , 2019 , 20, 1469-1471	21.7	2
45	Editorial Comment. <i>Journal of Urology</i> , 2019 , 202, 1247	2.5	
44	Robotic Assisted Radical Cystectomy vs Open Radical Cystectomy: Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2019 , 201, 715-720	2.5	66
43	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. <i>European Urology</i> , 2019 , 75, 523-531	10.2	33
42	Can exercise delay transition to active therapy in men with low-grade prostate cancer? A multicentre randomised controlled trial. <i>BMJ Open</i> , 2018 , 8, e022331	3	9
41	Enduring epigenetic landmarks define the cancer microenvironment. <i>Genome Research</i> , 2018 , 28, 625-6	33 .7	60
40	Development of Indicators to Assess Quality of Care for Prostate Cancer. <i>European Urology Focus</i> , 2018 , 4, 57-63	5.1	11
39	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018 , 73, 178-211	10.2	313
38	Laparoscopic and robot-assisted vs open radical prostatectomy for the treatment of localized prostate cancer: a Cochrane systematic review. <i>BJU International</i> , 2018 , 121, 845-853	5.6	54
37	Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells. <i>BJU International</i> , 2018 , 121, 971-978	5.6	27
36	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. <i>European Urology</i> , 2018 , 74, 562-572	10.2	51
35	Trajectories of quality of life, life satisfaction, and psychological adjustment after prostate cancer. <i>Psycho-Oncology</i> , 2017 , 26, 1576-1585	3.9	62
34	Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. <i>Nature Communications</i> , 2017 , 8, 13671	17.4	128
33	Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure. <i>Nature Reviews Urology</i> , 2017 , 14, 312-322	5.5	37
32	Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. <i>European Urology</i> , 2017 , 72, 492-495	10.2	52
31	Age Related Differences in Responsiveness to Sildenafil and Tamsulosin are due to Myogenic Smooth Muscle Tone in the Human Prostate. <i>Scientific Reports</i> , 2017 , 7, 10150	4.9	5

(2013-2017)

30	PSA testing for men at average risk of prostate cancer. <i>Public Health Research and Practice</i> , 2017 , 27,	5.1	3
29	Impact of branding on public awareness of healthcare-related governing bodies: a pilot study of the Urological Society of Australia and New Zealand brand. <i>BJU International</i> , 2016 , 118 Suppl 3, 23-29	5.6	14
28	Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia. <i>BMC Urology</i> , 2016 , 16, 54	2.2	9
27	Enhancing active surveillance of prostate cancer: the potential of exercise medicine. <i>Nature Reviews Urology</i> , 2016 , 13, 258-65	5.5	23
26	Obesity does not promote tumorigenesis of localized patient-derived prostate cancer xenografts. <i>Oncotarget</i> , 2016 , 7, 47650-47662	3.3	12
25	Prostate cancer screening in Primary Health Care: the current state of affairs. <i>SpringerPlus</i> , 2015 , 4, 78		9
24	Transperineal biopsy prostate cancer detection in first biopsy and repeat biopsy after negative transrectal ultrasound-guided biopsy: the Victorian Transperineal Biopsy Collaboration experience. <i>BJU International</i> , 2015 , 116, 568-76	5.6	29
23	Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer. <i>Prostate</i> , 2015 , 75, 1475-83	4.2	28
22	National nephrectomy registries: Reviewing the need for population-based data. <i>Korean Journal of Urology</i> , 2015 , 56, 607-13		4
21	Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. <i>European Urology</i> , 2015 , 67, 496-503	10.2	73
20	Defining a standard set of patient-centered outcomes for men with localized prostate cancer. <i>European Urology</i> , 2015 , 67, 460-7	10.2	136
19	Prostate cancer: care beyond prostate cancer-improving patient outcomes. <i>Nature Reviews Urology</i> , 2014 , 11, 669-71	5.5	1
18	A pro-tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment. <i>Journal of Pathology</i> , 2014 , 234, 86-98	9.4	33
17	Sepsis and SuperbugsS should we favour the transperineal over the transrectal approach for prostate biopsy?. <i>BJU International</i> , 2014 , 114, 384-8	5.6	136
16	Androgen deprivation therapy complications. <i>Endocrine-Related Cancer</i> , 2014 , 21, T119-29	5.7	33
15	A preclinical xenograft model of prostate cancer using human tumors. <i>Nature Protocols</i> , 2013 , 8, 836-48	3 18.8	80
14	The Prostate Cancer Registry: monitoring patterns and quality of care for men diagnosed with prostate cancer. <i>BJU International</i> , 2013 , 111, E158-66	5.6	44
13	Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy. <i>Psycho-Oncology</i> , 2013 , 22, 2169-76	3.9	32

12	Holmium Laser Enucleation of the Prostate: Comparison of Immediate Postoperative Outcomes in Patients with and without Antithrombotic Therapy. <i>Current Urology</i> , 2013 , 7, 28-33	1.7	30
11	Monitoring cardiovascular health in men with prostate cancer treated with androgen deprivation therapy. <i>International Journal of Urological Nursing</i> , 2012 , 6, 35-41	0.8	2
10	Long-term experience of residual symptoms following treatment for localized prostate cancer: An Australian sample. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2007 , 3, 199-206	1.9	7
9	Diagnosing prostate cancer - what GPs need to know. Australian Family Physician, 2007, 36, 345-7		3
8	Management of superficial bladder cancer in Victoria: 1990 and 1995. <i>ANZ Journal of Surgery</i> , 2005 , 75, 270-4	1	5
7	PSA testing. Australian Family Physician, 2003 , 32, 396		
6	Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. <i>Acta Oncolgica</i> , 2002 , 41, 425-9	3.2	96
5	Nephron-sparing surgery for small incidental renal cell carcinoma. ANZ Journal of Surgery, 2001, 71, 34	9-353	3
4	The metaplastic effects of estrogen on mouse prostate epithelium: proliferation of cells with basal cell phenotype. <i>Endocrinology</i> , 2001 , 142, 2443-50	4.8	86
3	Radical prostatectomy: what do the patients really think of surgery?. Medical Journal of Australia,		
	1998, 168, 477-8	4	5
2		4	25